Dr Reddy's gains over 3% on new drug launch in the US market

The company launched its generic version of fesoterodine fumarate extended-release tablets that can be used for treating overactive bladder in the US market.

Dr Reddy’s gains over 3% on new drug launch in US market
SI Reporter Mumbai
2 min read Last Updated : Jul 11 2022 | 11:13 AM IST
Shares of Dr Reddy’s Laboratories were up 3.4 per cent to Rs 4,553.70 on the BSE in Monday’s trade in an otherwise weak market after they launched generic version of fesoterodine fumarate extended-release tablets to treat overactive bladder in the US market.

The company along with its subsidiaries announced the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) extended-release tablets in the U.S. market approved by the U.S. Food and Drug Administration (USFDA). The company’s fesoterodine fumarate extended-release tablets are available in 4 mg and 8 mg tablets, each in bottle count sizes of 30.

According to IQVIA, the Toviaz brand had sales of approximately $211 million MAT in the US over twelve months that ended in May 2022.

Meanwhile, last week USFDA completed pre-approval inspection (PAI) of the company’s formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh. The company has been issued a Form 483 with two observations, which the company said it will address within the stipulated timeline.

In the past three months, Dr Reddy’s outperformed the market by gaining 4 per cent, against 8 per cent decline in the S&P BSE Sensex. However, it has slipped 17 per cent in a year as compared to 3.5 per cent rise in the benchmark index.

Analysts at Nirmal Bang expect the company to deliver growth across their business segments. "In North America, which is the single largest market for the company, it has multiple limited competition opportunities targeted through its pipeline and gRevlimid is one of them that will fructify in the near term," the brokerage firm said.

That apart, they also foresee the company to make progress in improving its rankings in India. The company targets Nutraceuticals and OTC segments in India, where it currently has a small presence, but has larger aspirations. Emerging Markets (EM) should also continue to grow as the company will continue to expand its portfolio and footprint.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Buzzing stocksDr ReddysPharma stocksUSFDAMarket trendsstocks to watch

Next Story